The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

KEYTRUDA is indicated for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS ...

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

Last week the FDA approved Keytruda as a perioperative (before and after surgery) treatment for resectable locally advanced head and neck cancer patients whose tumors express PD-L1 at a positive ...

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1 Mature overall survival data builds on ...

Merck, known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA ®, Merck’ s anti-PD-1 therapy, as a perioperative ...

Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results impressed Wall Street in head and neck ...

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1 May 05, 2025 8:00 AM ET Immutep Limited (PRRUF) ...

The trial tests BNT113, a biological treatment administered via IV injection, in combination with pembrolizumab, an IV infusion, to enhance therapeutic outcomes for patients with specific head and ...

Shares of Merus NV (NASDAQ:MRUS) were trading at $54.35, up $12.75, or 30%, on interim data as of Feb. 27 from the phase II trial of bispecific antibody petosemtamab in combination with Merck & Co.